Guggenheim Initiates Coverage On ArriVent BioPharma with Buy Rating, Announces Price Target of $45

+6.31%

ArriVent BioPharma, Inc.

AVBP

0.00

Guggenheim analyst Michael Schmidt initiates coverage on ArriVent BioPharma (NASDAQ: AVBP) with a Buy rating and announces Price Target of $45.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.

Recommend

Nuvation Bio (NUVB): Valuation in Focus as Earnings Anticipation and Revenue Forecasts Drive Analyst Optimism

Royalty Pharma's Major Royalty Deals and $2B Raise Could Be a Game Changer for RPRX

Does CorMedix’s Recent Clinical Advances Signal a Missed Opportunity in 2025?

Pyxis Oncology Q3 EPS $(0.35) Misses $(0.34) Estimate

IGC Pharma Expands AI-Powered In-Silico Platform To Accelerate Alzheimer's Drug Discovery

Ocular Therapeutix (OCUL): Assessing Valuation After Analyst Upgrades and Axpaxli Clinical Progress

Sarepta Therapeutics Stock Is Tumbling After The Close: Here's Why

Liquidia (LQDA) Losses Worsen Despite Strong 43.7% Revenue Growth Forecast—Profitability Narrative in Focus